KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Net Income (2016 - 2025)

Historic Net Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$45.1 million.

  • Supernus Pharmaceuticals' Net Income fell 21719.61% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 13194.75%. This contributed to the annual value of $73.9 million for FY2024, which is 551284.19% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Net Income stood at -$45.1 million, which was down 21719.61% from $22.5 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Net Income peaked at $38.5 million during Q3 2024, and registered a low of -$45.1 million during Q3 2025.
  • Moreover, its 5-year median value for Net Income was $7.8 million (2022), whereas its average is $8.1 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Net Income surged by 250652.96% in 2024, and later plummeted by 964112.9% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Net Income (Quarter) stood at $2.4 million in 2021, then skyrocketed by 943.45% to $25.5 million in 2022, then plummeted by 95.39% to $1.2 million in 2023, then skyrocketed by 1208.68% to $15.4 million in 2024, then tumbled by 393.41% to -$45.1 million in 2025.
  • Its Net Income stands at -$45.1 million for Q3 2025, versus $22.5 million for Q2 2025 and -$11.8 million for Q1 2025.